Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth
暂无分享,去创建一个
Qingmei He | Xiao-jing Yang | Na Liu | Jun Ma | Yin Zhao | Shiwei He | Yang Chen | W. Luo | Lei Chen | Xiaomin Li | Yuan Zhang | Shengyan Huang | Yingqin Li
[1] L. Perera,et al. NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells , 2021, Cancers.
[2] T. Hung,et al. Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat , 2021, International journal of molecular sciences.
[3] T. Efferth,et al. Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction , 2020, Cells.
[4] Jianzhong Du,et al. Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis. , 2020, Biomaterials.
[5] J. Yeh,et al. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] Tie Wang,et al. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer , 2020, Frontiers in Immunology.
[7] A. Dart. Suppressed fate , 2019, Nature Reviews Cancer.
[8] L. Astolfi,et al. Cisplatin-Induced Ototoxicity: Updates on Molecular Targets. , 2019, Trends in molecular medicine.
[9] A. C. Gasparovic,et al. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[10] Yingqin Li,et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. , 2019, The New England journal of medicine.
[11] J. Chen,et al. Gemcitabine nanoparticles promote antitumor immunity against melanoma. , 2019, Biomaterials.
[12] Qingmei He,et al. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study , 2018, Cancer communications.
[13] M. Dolan,et al. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities , 2018, Clinical Cancer Research.
[14] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[15] G. Pozzi,et al. Type M Resistance to Macrolides Is Due to a Two-Gene Efflux Transport System of the ATP-Binding Cassette (ABC) Superfamily , 2018, Front. Microbiol..
[16] B. Goh,et al. Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models , 2018, Signal Transduction and Targeted Therapy.
[17] K. Engeland. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM , 2017, Cell Death and Differentiation.
[18] Nathan S. Abell,et al. Chromatin Regulates Genome Targeting with Cisplatin , 2017, Angewandte Chemie.
[19] Jianji Pan,et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial , 2016, The Lancet.
[20] S. Na'ara,et al. Gemcitabine resistance in pancreatic ductal adenocarcinoma. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[21] D. Jodrell,et al. CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. , 2015, Cancer research.
[22] John C Ashton,et al. Drug combination studies and their synergy quantification using the Chou-Talalay method--letter. , 2015, Cancer research.
[23] H. Sze,et al. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] K. Venkatasubbarao,et al. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer , 2013, Molecular Cancer.
[25] A. V. van Kuilenburg,et al. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. , 2012, Cancer letters.
[26] C. Her,et al. MutS homologue hMSH5: role in cisplatin-induced DNA damage response , 2012, Molecular Cancer.
[27] J. Glover,et al. ATR autophosphorylation as a molecular switch for checkpoint activation. , 2011, Molecular cell.
[28] Shazib Pervaiz,et al. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. , 2011, Biochimica et biophysica acta.
[29] S. Lakhani,et al. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes , 2010, Oncogene.
[30] A. Balmain,et al. Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.
[31] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[32] M. Kurokawa,et al. Caspases and Kinases in a Death Grip , 2009, Cell.
[33] Anindya Dutta,et al. p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.
[34] Ying Sun,et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. , 2009, International journal of radiation oncology, biology, physics.
[35] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[36] Christopher K. Glass,et al. Tyrosine Dephosphorylation of H2AX Modulates Apoptosis and Survival Decisions , 2009, Nature.
[37] Alexei Degterev,et al. Expansion and evolution of cell death programmes , 2008, Nature Reviews Molecular Cell Biology.
[38] James M. Roberts,et al. CDK inhibitors: cell cycle regulators and beyond. , 2008, Developmental cell.
[39] M. Kastan,et al. A Novel ATM-Dependent Pathway Regulates Protein Phosphatase 1 in Response to DNA Damage , 2008, Molecular and Cellular Biology.
[40] Bernard Ducommun,et al. CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.
[41] W. Earnshaw,et al. Chk1 is required for spindle checkpoint function. , 2007, Developmental cell.
[42] J. Zisowsky,et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. , 2007, Biochemical pharmacology.
[43] Anke Sparmann,et al. Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.
[44] E. Mini,et al. Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] S. West,et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair , 2005, Nature.
[46] K. Vermeulen,et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. , 2003, International journal of radiation oncology, biology, physics.
[47] T. Ouchi,et al. Cell Cycle Differences in DNA Damage-induced BRCA1 Phosphorylation Affect Its Subcellular Localization* , 2003, The Journal of Biological Chemistry.
[48] M. Kastan,et al. The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.
[49] G. Peters,et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines , 1999, British Journal of Cancer.
[50] Y Taya,et al. A role for ATR in the DNA damage-induced phosphorylation of p53. , 1999, Genes & development.
[51] J. Beijnen,et al. MOLECULAR CANCER THERAPEUTICS | CANCER BIOLOGYAND TRANSLATIONAL STUDIES ABCB1andABCG2RestrictBrain andTestisAccumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib , 2021 .
[52] Li-Zhi Liu,et al. INTENSITY-MODULATED RADIOTHERAPY VERSUS CONVENTIONAL TWO-DIMENSIONAL RADIOTHERAPY INFLUENCE THE TREATMENT RESULTS IN NASOPHARYNGEAL CARCINOMA PATIENTS ? , 2011 .